Huntington’s disease (HD) stands among the most formidable challenges in neuroscience – an inherited neurodegenerative disorder with profound physical, cognitive, and psychiatric impact. For decades, therapeutic progress was hindered by the disease’s complex pathophysiology and the lack of disease-modifying treatments. 

Today, however, the landscape for HD clinical trials is undergoing a transformative shift. Advances in genetic science, biomarker discovery, and therapeutic platforms are driving a new wave of investigational treatments. These innovations are not only expanding the scientific horizon, but also fueling a surge in early- and late-phase clinical trials. For Sponsors, this momentum presents a unique opportunity: to address a critical unmet need, to pioneer a cutting-edge neurology development, and to contribute to a global movement in precision medicine. For trial sites, it signals the beginning of deeper collaboration and clinical innovation in an area that urgently needs new hope. 

 

Emerging Therapies in Huntington’s Disease Clinical Trials  

HD research is advancing rapidly, driven by progress in gene-targeted therapies, small molecule modulators, and regenerative medicine. These developments offer promising avenues to slow or halt diseases progression, presenting significant opportunities for pharmaceutical sponsors and clinical sites. This section explores the most promising developments in each of these areas, highlighting key clinical trial data and what it could mean for the future of HD treatment. 

Gene Silencing & Editing Approaches 

HD, characterized by a single-gene mutation, presents a prime target for precision genetic therapies aimed at modifying disease progression. The monogenic nature of HD has catalyzed the development of targeted interventions designed to lower or eliminate the production of mutant huntingtin (mHTT) protein, which is central to the disease’s pathology.  

Key gene-slicing therapies under active clinical investigation include: 

• Antisense oligonucleotides (ASOs): these synthetic strands of nucleic acid bind to mHTT mRNA promoting its degradation and thereby reducing mHTT protein synthesis. 
• RNA interference (RNAi): utilizing small interfering RNAs (siRNAs), this approach targets mHTT mRNA for deregulation. 
• CRISPR-based gene editing: CRISPR/Cas9 offers the potential to directly modify or silence the mutant mHTT gene. Precision studies have demonstrated that CRISPR-mediated disruption of HTT gene in mouse models leads to reduced mHTT aggregation and improved motor functions. 

For Sponsors and clinical sites these innovative platforms represent a significant opportunity to engage in pioneering research for HD clinical trials that could redefine therapeutic approaches for neurodegenerative diseases. Several gene-targeted therapies have advanced into clinical development, each leveraging a distinct platform to reduce or silence mutant huntingtin expression. Below are a few promising candidates currently under investigation. 

• Tominersen (Roche/Ionis Pharmaceuticals): With GENERATION-HD1 trial initially paused due to mixed Phase III results, tominersen is now being reconsidered in a revised dosing strategy and population subset, potentially addressing concerns about over-suppression of wild-type huntingtin. 
• WVE-003 (Wave Life Sciences): This allele-selective ASO targets only the mutant HTT allele, preserving the wild-type protein. Interim results from the SELECT-HD trial demonstrated promising allele-specific mHTT lowering in cerebrospinal fluid with favorable tolerability. 
• AMT-130 (uniQure): A gene therapy candidate delivered via AAV5 vector, AMT-130 introduces microRNAs to silence mHTT expression. Based on early Phase I/II data, AMT-130 high dose recipients shown an 80% reduction in progression compared to controls. The therapy has received FDA Breakthrough Therapy Designation. 

Small Molecule & Modulator Programs 

While gene therapies are revolutionizing the treatment landscape in HD, small molecule therapeutics offer practical advantages, including oral administration and ease of manufacturing, making them accessible options for broader patient populations in HD clinical trials. Targeting pathways, such as RNA splicing, cellular signaling, and neuroprotection, aim to slow disease progression, stabilize function, and improve quality of life. As clinical research evolves, several small molecule candidates have emerged with promising safety and efficacy profiles. The following candidates exemplify how these compounds can modulate key biological pathways to slow disease progression and improve patient outcomes. 

• Pridopidine (Prilenia Therapeutics): A sigma-1 receptor agonist thought to support cellular homeostasis and neuroprotection. While Phase III PROOF-HD did not meet its primary endpoints, subgroups analyses revealed benefits in patients not taking antidopaminergic medications, including improvement in functional and cognitive measures. 
• PTC518 (PTC Therapeutics): An oral splicing modulator that lowers mHTT levels by affecting HTT mRNA. Phase II PIVOT-HD data confirmed target engagement, mHTT reduction, and a positive safety profile, paving the way for a global development. PTC Therapeutics has entered a $2.9 billion partnership with Novartis for further development. 

Collectively, these programs reflect the growing momentum in HD drug discovery and development. Small molecules like pridopidine and PTC518 offer important mechanistic diversity in the treatment landscape, complementing genetic and cell-based strategies. Their ease of use, favorable pharmacokinetics, and potential for long-term administration make them attractive options in the clinical trials pipeline—particularly for patients in early and mid-stages of the disease. Continued investment and clinical validation will be key to translating these candidates into approved therapies that can reach patients quickly and effectively. 

Cell & Regenerative Therapies 

While most therapeutic approaches in HD focus on halting or slowing the degenerative process, regenerative medicine seeks to go a step further—by repairing or replacing the neurons lost to HD. Still in its nascent stages, stem cells-based therapies are being explored through academic and industry collaborations, focusing on transplantation strategies to rebuild neural circuits. These therapies represent a bold and forward-looking approach to treating HD. The ability to not only modify but also reverse disease pathology could fundamentally alter how we think about neurodegenerative conditions. Several clinical trials and preclinical studies are exploring stem cell-based therapies: 

• Dental Pulp Stem Cell Therapy (Phase 3): A Phase 3 clinical trial is currently underway to evaluate the efficacy of dental pulp stem cells (DPSCs) in treating early to moderate HD. This randomized, double-blind, placebo-controlled study aims to enroll 120 participants and assess the therapy’s effectiveness over a one-year period.  
• SUPT4H1-Edited iPSC Therapy (Preclinical): A preclinical study demonstrated that induced pluripotent stem cell-derived neural precursor cells, edited to suppress the SUPT4H1 gene, improved motor function and reduced mutant huntingtin protein expression in HD mouse models. This approach suggests potential for autologous stem cell therapies with reduced immunogenicity. 
• UC Davis Stem Cell Program: Researchers at UC Davis are preparing for human clinical trials involving the transplantation of stem cells to replace damaged neurons in HD patients. The goal is to reduce harmful protein accumulation and restore neural function. 
• Trailhead Biosystems: Trailhead Biosystems is developing a mesenchymal stem cell (MSC) therapy targeting HD, currently in the preclinical research stage. The company utilizes its High-Dimensional Design of Experiments (HD-DoE) platform to optimize cell growth and differentiation processes, aiming to produce precise cellular therapies. As of May 2025, there are no registered clinical trials for this therapy, and it remains in the preclinical phase.  

 

Biomarkers and Digital Innovation in Huntington’s Disease Clinical Trials 

As the complexity of neuroscience clinical trials grows, so too does the need for more sensitive, objective, and scalable methods to assess therapeutic impact. In HD, where disease progression can be gradual and heterogeneous, the identification and validation of robust biomarkers are transforming how clinical trials are designed and executed. Biomarkers offer a window into underlying disease biology and treatment response—enabling faster, more data-driven decision-making. Complementing these molecular tools are digital innovations such as wearable technologies and remote monitoring platforms, which capture real-time functional data outside of clinical settings. Together, these advances are driving a shift toward more patient-centric, decentralized clinical trials, while also increasing the statistical power of studies and reducing reliance on subjective endpoints. For sponsors and CROs alike, the integration of biomarkers and digital health tools is not just enhancing data quality—it’s accelerating timelines and improving the feasibility of trials in rare and complex disorders like HD. 

• Fluid biomarkers: Mutant huntingtin protein (mHTT) levels and neurofilament light chain (NfL), are increasingly utilized to monitor disease progression and therapeutic response. 
• mHTT in Cerebrospinal Fluid (CSF): Elevated mHTT levels in CSF correlate with disease progression, serving as a pharmacodynamic marker in clinical trials.  
• NfL in CSF and Plasma: NfL concentrations rise with neuronal damage, offering a sensitive measure of disease activity. Recent studies demonstrate that mHTT-lowering therapies can stabilize or reduce NfL levels, indicating potential neuroprotective effects. 
• Digital biomarkers and wearables: Remote monitoring technologies are now capturing motor and cognitive function in real-time, enabling decentralized clinical trials and reducing patient burden. These advances not only support patient engagement but also yield higher-resolution data, enabling continues real world monitoring of patients. 
• Wearable Sensors: Devices equipped with accelerometers and gyroscopes can detect subtle motor changes, providing quantitative data on movement patterns. Machine learning algorithms enhance the analysis of this data, improving the detection of disease-related alterations. 
• Remote Monitoring Platforms: Smartphone applications and connected devices allow for the collection of cognitive and behavioral data outside clinical settings, reducing patient burden and increasing data richness. 

The convergent of fluid biomarkers and digital health technologies offers a comprehensive framework for HD clinical trials: 

• Enhanced Data Quality: combining molecular and digital data provides a multifaced view of disease progression and treatment response. 
• Accelerated Timelines: objective, continuous data collection enables faster decision-making and adaptive trial design.  
• Improved Feasibility: remote monitoring reduces logistical challenges, facilitating the inclusion of diverse patient populations. 

For Sponsors and CROs, embracing these innovations is crucial for the successful execution of HD clinical trials. 

 

Clinical Development Challenges and Solutions 

While the recent breakthroughs in HD research have generated significant momentum, translating scientific innovations remains a complex and demanding journey. As with many rare neurodegenerative disorders, HD clinical trials encounter distinctive operational and logistic hurdles that can slow progress and jeopardize outcomes. Recruiting and retaining participants across multi-year studies poses one of the greatest challenges. The rarity of the disease, coupled with the emotional and physical toll it takes on patients and families, makes identifying eligible and willing participants difficult. Leveraging global site networks and registries can expand access to genetically confirmed patients. Even after enrolment, the progressive nature of HD often leads to declining motor and cognitive function, which can impact both protocol compliance and data quality over time.

Moreover, heterogeneity in symptom onset, progression rate, and comorbidities complicates trial design and endpoint selection. Sponsors must navigate a narrow therapeutic window while ensuring that endpoints remain clinically meaningful, statistically robust, and regulatory-compliant. To overcome these challenges, a strategic, multidisciplinary approach is essential—one that combines scientific precision with operational flexibility and places the patient experience at the centre of study design. Decentralized clinical trials (DCTs) and hybrid protocols are proving essential in improving patient retention in long-duration neuroscience studies. These models minimize the need for frequent site visits through remote monitoring, telemedicine, and home nursing support—reducing burden while improving engagement and compliance. Partnerships with patient advocacy organizations, such as the Huntington’s Disease Society of America (HDSA), the European Huntington Association and local patient organizations foster trust and facilitate communication with patient and caregivers. These alliances help refine study design, disseminate information, and support recruitment through grassroots outreach. The alignment of operational innovation with clinical and patient-centric insights, enables Sponsors and CROs in navigating the complexity of HD more efficiently. Strategic planning, global coordination, and meaningful stakeholder engagement are not just best practices. They are essential ingredients in accelerating the delivery of life-changing therapies to the Huntington’s communities. 

 

Conclusion: Collaboration as the Catalyst for Progress  

The clinical development pipeline for HD has never been more dynamic and promising. While a cure remains elusive, the alignment of breakthrough science, validated biomarkers, and innovative clinical trial methodologies marks a pivot shift in trajectory of HD research. This is defining moment, not only for field of neuroscience but for the rare disease community at large. Yet, innovation alone is not enough. The path from molecule to medicine demands executional excellence, scientific rigor, and above all collaboration. For sponsors, the key to success lies in selecting the right partners the challenge – those who bring not only operational agility and regulatory know-how but a deep understanding of patient journey and the complexity of neurodegenerative conditions. Mid-sized contract research organization (CROs) with global infrastructure and focused neuroscience expertise are uniquely positioned to meet these demands. They offer the flexibility to tailor solutions, the speed to adapt to emerging data, and the commitment to deliver with quality and compassion. 

Looking ahead, advancing HD therapies will require more than cutting-edge platforms; it will require truly integrated scientific strategies and partnerships. It is through this collaborative spirit that the potential of next-generation therapies can be fully unlocked—and the promise of a better future delivered to the HD community . 

 

About TFS HealthScience CRO 

TFS HealthScience plays a pivotal role in advancing precision medicine and neuroscience research. By partnering with academic institutions and patient advocacy organizations, TFS drives innovation in clinical trial design and execution. Through expertise in biomarker validation, patient recruitment, and adaptive trial strategies, TFS supports the development of tailored therapies that address the complexities of neurological disorders. Discover how TFS is shaping the future of neurology research with its integrated and patient-centered approach. Visit our neuroscience expertise page or contact a TFS representative today.  

Interested in learning about five more top neurology CROs leading the industry in brain research? Visit our article here!